Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: Rick K who wrote (408)	11/18/1997 9:57:00 AM
From: AgAuUSA	Respond to of 1906

biz.yahoo.com

To: Rick K who wrote (408)	11/18/1997 10:21:00 PM
From: Alan C. Zezula	Read Replies (1) \| Respond to of 1906

Elamex hasn't even begun the application process for approval by the FDA. I think this will be a saving grace for Amgn as they move slower than molasses in Jan. for approvals. Plus it doesn't sound like the patent infringement suit has been settled just yet. News was out on 17th. Amgn today 52 1/4 -- 11/16. If it were to have a terribly adverse affect on Amgn wouldn't it have been reflected in today's trading? Al

To: Rick K who wrote (408)	3/7/1998 5:17:00 PM
From: Henry Niman	Respond to of 1906

Anyone attend the hematopoeisis meeting in Lake Tahoe? I'm trying to get more info on LGND's presentation on an oral replacement for G-CSF.

To: Rick K who wrote (408)	3/7/1998 10:27:00 PM
From: Henry Niman	Respond to of 1906

Look out below. I have updated the SBH Alliance Table at home.att.net to include more details of the little molecule that mimics G-CSF (with exquisite specificity) as well as a few recently (1998) issued relevant patents.